91 related articles for article (PubMed ID: 31216262)
21. EphA2 Targeted Doxorubicin-Nanoliposomes for Osteosarcoma Treatment.
Haghiralsadat F; Amoabediny G; Naderinezhad S; Nazmi K; De Boer JP; Zandieh-Doulabi B; Forouzanfar T; Helder MN
Pharm Res; 2017 Dec; 34(12):2891-2900. PubMed ID: 29110283
[TBL] [Abstract][Full Text] [Related]
22. [Inhibition of Combination of Icaritin and Doxorubicin on Human Osteosarcoma MG-63 Cells in vitro].
Lin SW; Li XQ; Liu SY; Shi JM; Xu JH; Mao LH; Yin M
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2016 Jun; 36(6):729-34. PubMed ID: 27491234
[TBL] [Abstract][Full Text] [Related]
23. Targeted osteosarcoma chemotherapy using RGD peptide-installed doxorubicin-loaded biodegradable polymeric micelle.
Fang Z; Sun Y; Xiao H; Li P; Liu M; Ding F; Kan W; Miao R
Biomed Pharmacother; 2017 Jan; 85():160-168. PubMed ID: 27930982
[TBL] [Abstract][Full Text] [Related]
24. Multiple pathways are involved in drug resistance to doxorubicin in an osteosarcoma cell line.
Rajkumar T; Yamuna M
Anticancer Drugs; 2008 Mar; 19(3):257-65. PubMed ID: 18510171
[TBL] [Abstract][Full Text] [Related]
25. A novel derivative of doxorubicin, AD198, inhibits canine transitional cell carcinoma and osteosarcoma cells in vitro.
Rathore K; Cekanova M
Drug Des Devel Ther; 2015; 9():5323-35. PubMed ID: 26451087
[TBL] [Abstract][Full Text] [Related]
26. Visfatin is involved in the cisplatin resistance of osteosarcoma cells via upregulation of Snail and Zeb1.
Wang D; Qian G; Wang J; Wang T; Zhang L; Yang P; Lin F
Cancer Biol Ther; 2019; 20(7):999-1006. PubMed ID: 30975015
[TBL] [Abstract][Full Text] [Related]
27. Targeting acute hypoxic cancer cells by doxorubicin-immunoliposomes directed by monoclonal antibodies specific to RON receptor tyrosine kinase.
Guin S; Ma Q; Padhye S; Zhou YQ; Yao HP; Wang MH
Cancer Chemother Pharmacol; 2011 May; 67(5):1073-83. PubMed ID: 20658288
[TBL] [Abstract][Full Text] [Related]
28. Co-delivery of doxorubicin and recombinant plasmid pHSP70-Plk1-shRNA by bacterial magnetosomes for osteosarcoma therapy.
Cheng L; Ke Y; Yu S; Jing J
Int J Nanomedicine; 2016; 11():5277-5286. PubMed ID: 27822032
[TBL] [Abstract][Full Text] [Related]
29. Gold nanoconjugates reinforce the potency of conjugated cisplatin and doxorubicin.
Iram S; Zahera M; Khan S; Khan I; Syed A; Ansary AA; Ameen F; Shair OHM; Khan MS
Colloids Surf B Biointerfaces; 2017 Dec; 160():254-264. PubMed ID: 28942160
[TBL] [Abstract][Full Text] [Related]
30. Long noncoding RNA SNHG12 mediates doxorubicin resistance of osteosarcoma via miR-320a/MCL1 axis.
Zhou B; Li L; Li Y; Sun H; Zeng C
Biomed Pharmacother; 2018 Oct; 106():850-857. PubMed ID: 30119255
[TBL] [Abstract][Full Text] [Related]
31. Combining GRP78 suppression and MK2206-induced Akt inhibition decreases doxorubicin-induced P-glycoprotein expression and mitigates chemoresistance in human osteosarcoma.
Xia YZ; Yang L; Xue GM; Zhang C; Guo C; Yang YW; Li SS; Zhang LY; Guo QL; Kong LY
Oncotarget; 2016 Aug; 7(35):56371-56382. PubMed ID: 27486760
[TBL] [Abstract][Full Text] [Related]
32. Effect of thermosensitive liposomal doxorubicin with hyperthermia on primary tumor and lung metastases in hamster osteosarcoma.
Shimose S; Sugita T; Nitta Y; Kubo T; Ikuta Y; Murakami T
Int J Oncol; 2001 Sep; 19(3):585-9. PubMed ID: 11494040
[TBL] [Abstract][Full Text] [Related]
33. Modulation of multidrug resistance-associated protein 1 (MRP1) by p53 mutant in Saos-2 cells.
Tsang WP; Chau SP; Fung KP; Kong SK; Kwok TT
Cancer Chemother Pharmacol; 2003 Feb; 51(2):161-6. PubMed ID: 12647018
[TBL] [Abstract][Full Text] [Related]
34. The effective combination therapy against human osteosarcoma: doxorubicin plus curcumin co-encapsulated lipid-coated polymeric nanoparticulate drug delivery system.
Wang L; Wang W; Rui Z; Zhou D
Drug Deliv; 2016 Nov; 23(9):3200-3208. PubMed ID: 26987435
[TBL] [Abstract][Full Text] [Related]
35. Thiolated pectin-doxorubicin conjugates: Synthesis, characterization and anticancer activity studies.
Cheewatanakornkool K; Niratisai S; Manchun S; Dass CR; Sriamornsak P
Carbohydr Polym; 2017 Oct; 174():493-506. PubMed ID: 28821097
[TBL] [Abstract][Full Text] [Related]
36. Cardiomyocyte apoptosis vs autophagy with prolonged doxorubicin treatment: comparison with osteosarcoma cells.
Tacar O; Indumathy S; Tan ML; Baindur-Hudson S; Friedhuber AM; Dass CR
J Pharm Pharmacol; 2015 Feb; 67(2):231-43. PubMed ID: 25208656
[TBL] [Abstract][Full Text] [Related]
37. Estrogen-functionalized liposomes grafted with glutathione-responsive sheddable chotooligosaccharides for the therapy of osteosarcoma.
Yin X; Feng S; Chi Y; Liu J; Sun K; Guo C; Wu Z
Drug Deliv; 2018 Nov; 25(1):900-908. PubMed ID: 29644882
[TBL] [Abstract][Full Text] [Related]
38. Doxorubicin induces ZAKα overexpression with a subsequent enhancement of apoptosis and attenuation of survivability in human osteosarcoma cells.
Fu CY; Tseng YS; Chen MC; Hsu HH; Yang JJ; Tu CC; Lin YM; Viswanadha VP; Kuo WW; Huang CY
Environ Toxicol; 2018 Feb; 33(2):191-197. PubMed ID: 29105997
[TBL] [Abstract][Full Text] [Related]
39. Drug resistance modification using pulsing electromagnetic field stimulation for multidrug resistant mouse osteosarcoma cell line.
Hirata M; Kusuzaki K; Takeshita H; Hashiguchi S; Hirasawa Y; Ashihara T
Anticancer Res; 2001; 21(1A):317-20. PubMed ID: 11299755
[TBL] [Abstract][Full Text] [Related]
40. A Second-Generation Proteasome Inhibitor and Doxorubicin Modulates IL-6, pSTAT-3 and NF-kB Activity in MDA-MB-231 Breast Cancer Cells.
Vyas D; Lopez-Hisijos N; Shah P; Deshpande KS; Basson MD; Vyas A; Chaturvedi LS
J Nanosci Nanotechnol; 2017 Jan; 17(1):175-85. PubMed ID: 29617099
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
